CN1022325C - 咪唑烷二酮衍生物的制备方法 - Google Patents

咪唑烷二酮衍生物的制备方法 Download PDF

Info

Publication number
CN1022325C
CN1022325C CN88106484A CN88106484A CN1022325C CN 1022325 C CN1022325 C CN 1022325C CN 88106484 A CN88106484 A CN 88106484A CN 88106484 A CN88106484 A CN 88106484A CN 1022325 C CN1022325 C CN 1022325C
Authority
CN
China
Prior art keywords
compound
product
methyl
spiro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN88106484A
Other languages
English (en)
Chinese (zh)
Other versions
CN1031702A (zh
Inventor
史蒂文·韦恩·戈尔茨坦
莱因哈德·萨杰斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1031702A publication Critical patent/CN1031702A/zh
Application granted granted Critical
Publication of CN1022325C publication Critical patent/CN1022325C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN88106484A 1987-09-04 1988-09-03 咪唑烷二酮衍生物的制备方法 Expired - Fee Related CN1022325C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US87/02196 1987-09-04
USPCT/US87/002196 1987-09-04
PCT/US1987/002196 WO1989001775A1 (en) 1987-09-04 1987-09-04 Azolidinedione derivatives

Publications (2)

Publication Number Publication Date
CN1031702A CN1031702A (zh) 1989-03-15
CN1022325C true CN1022325C (zh) 1993-10-06

Family

ID=22202540

Family Applications (1)

Application Number Title Priority Date Filing Date
CN88106484A Expired - Fee Related CN1022325C (zh) 1987-09-04 1988-09-03 咪唑烷二酮衍生物的制备方法

Country Status (21)

Country Link
EP (1) EP0306251A3 (enExample)
JP (1) JPS6471882A (enExample)
KR (1) KR900008841B1 (enExample)
CN (1) CN1022325C (enExample)
AU (1) AU595467B2 (enExample)
CS (1) CS273186B2 (enExample)
DD (1) DD273381A5 (enExample)
DK (1) DK488688A (enExample)
EG (1) EG18591A (enExample)
FI (1) FI901087A7 (enExample)
HU (1) HU204832B (enExample)
IL (1) IL87590A (enExample)
MX (1) MX12896A (enExample)
MY (1) MY103765A (enExample)
NO (1) NO901016L (enExample)
PH (1) PH24957A (enExample)
PL (1) PL156798B1 (enExample)
PT (1) PT88407B (enExample)
WO (1) WO1989001775A1 (enExample)
YU (1) YU46863B (enExample)
ZA (1) ZA886507B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068333A (en) * 1990-03-07 1991-11-26 Pfizer Inc. 6-chloro-3,4-dihydro-pyrano [2,3-b]pyridines having the R configuration
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
PT1873145E (pt) * 2005-04-21 2012-12-03 Ishihara Sangyo Kaisha Método de produção de um derivado do ácido nicotínico ou de um seu sal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
FR2455046A1 (fr) * 1979-04-25 1980-11-21 Science Union & Cie Nouvelles hydantoines, leur procede de preparation et leur emploi comme medicament
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
ATE11781T1 (de) * 1981-05-13 1985-02-15 Imperial Chemical Industries Plc Pharmazeutische zubereitungen, die spirosuccinimidderivate enthalten.

Also Published As

Publication number Publication date
PL274504A1 (en) 1989-05-02
DD273381A5 (de) 1989-11-15
NO901016D0 (no) 1990-03-02
YU167788A (en) 1990-06-30
PT88407A (pt) 1989-07-31
YU46863B (sh) 1994-06-24
DK488688A (da) 1989-04-07
AU595467B2 (en) 1990-03-29
FI901087A0 (fi) 1990-03-02
CN1031702A (zh) 1989-03-15
AU2184188A (en) 1989-03-09
NO901016L (no) 1990-05-02
PT88407B (pt) 1992-10-30
EG18591A (en) 1993-06-30
CS273186B2 (en) 1991-03-12
PH24957A (en) 1990-12-26
MX12896A (es) 1993-06-01
KR900008841B1 (ko) 1990-11-30
IL87590A (en) 1992-07-15
ZA886507B (en) 1990-04-25
DK488688D0 (da) 1988-09-02
FI901087A7 (fi) 1990-03-02
EP0306251A2 (en) 1989-03-08
HUT56106A (en) 1991-07-29
WO1989001775A1 (en) 1989-03-09
MY103765A (en) 1993-09-30
KR890005112A (ko) 1989-05-11
JPS6471882A (en) 1989-03-16
IL87590A0 (en) 1989-01-31
CS591188A2 (en) 1990-06-13
HU204832B (en) 1992-02-28
EP0306251A3 (en) 1990-08-01
PL156798B1 (pl) 1992-04-30
JPH0583554B2 (enExample) 1993-11-26

Similar Documents

Publication Publication Date Title
CN1056611C (zh) 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
CN1026322C (zh) 苯并哑唑衍生物的制备方法
CN1053230A (zh) 新的聚4-氨基-2-羟基-1-甲基化合物脲基衍生物的制备方法
CN1090634C (zh) 喜树碱的前药形式和类似物,及其药物用途
CN1771234A (zh) 吡咯并三嗪激酶抑制剂的制备方法
CN1142227A (zh) 新的噻唑烷-4-酮衍生物
EP0458551B1 (en) Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
CN87104099A (zh) 抗变态反应和消炎药剂
JPH0825877B2 (ja) 眼科治療用組成物
CN1048014C (zh) 取代的吡咯类化合物及其制法、药物组合物和用途
CN1022325C (zh) 咪唑烷二酮衍生物的制备方法
CN1078720A (zh) 丁二烯衍生物及其制备方法
CN1075480A (zh) 新型芳基羰基氨基烷基-二氢-氧代吡啶类化合物及其生产与应用
JPH0536436B2 (enExample)
CN1140525C (zh) 1-三氟甲基-4-羟基-7-哌啶基-氨甲基苯并二氢吡喃衍生物
CN1097005A (zh) 2-氰基-3-羟基丙烯酰胺类化合物及其制备和用途
CN1035116A (zh) 杂环型氧代-2，3-二氮杂萘基乙酸
JP3398391B2 (ja) アルドースレダクターゼ抑制剤として有用なｎ’−アルキル−スピロ−イソキノリン−ピロリジン テトラオン類およびその類似体
CN1303379A (zh) 作为氧化氮合酶抑制剂的含稠环取代基的2－氨基吡啶
JPH0573754B2 (enExample)
CN1445222A (zh) 苯并吡喃类化合物、其制备方法和用途
JP2010505919A (ja) 神経精神性障害の治療に有用なアリールピペラジン誘導体
CN1750821A (zh) 3－取代－4－芳基喹啉－2－酮衍生物的阻转异构体
JPS6130588A (ja) ベンゾ〔ｃ〕〔１，８〕ナフチリジン、その製造方法及びその使用、並びにこれらの化合物を含有する調製剤

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee